The commercial landscape for GLP-1 products is very different than for other pharmaceutical products. Demand is extremely high given the prevalence of obesity, direct-to-patient sales through social media and other channels, and public interest magnified by celebrity endorsement. When these factors overlap, pharmacovigilance (PV) activity increases quickly—and not always in predictable ways.
These products are being used across large patient populations outside of healthcare practitioner control, and the patient population includes both Type 2 diabetics and non-diabetic patients. Such a volume of potential users, which also includes the population that self-pays and does not go through insurance, will inevitably result in a higher rate of complaints and adverse event/reaction reporting (including lack of effect). More patients (especially those who are using the products without the oversight of a healthcare practitioner) generally means more variability in outcomes and more questions for healthcare providers.
The self-pay market adds another layer of complexity; many users have the prescribed indications for which GLP-1s were approved but are self-paying due to insurance denial (perhaps analogous to off-label use) and are focusing on the weight loss that such medications can provide. In such a scenario, there may be no clinical assessment of underlying conditions, and interactions with other medications being taken by the patient might impact the effectiveness of the GLP-1 and, perhaps, affect other underlying disease states. Indeed, there is little research on the most frequent adverse events associated with GLP-1 usage in disease states, such as Type 2 diabetes, so it is likely that we do not have a full picture of adverse events in the self-pay/off-label-use population. This will likely change soon as this group is motivated to report their adverse events.
This position is supported by recent FDA and EMA activity. The FDA has issued multiple GLP-1-specific safety communications, including evaluations of suicidal ideation reports, alerts on compounded semaglutide dosing errors causing hospitalizations, and enforcement actions targeting unapproved GLP-1 products. EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) opened and completed a class-wide GLP-1 signal review on suicidal and self-injurious thoughts/actions, demonstrating formal regulatory signal evaluation for the class. Lachman noted that the FDA recently issued a warning letter to a manufacturer for postmarketing adverse drug experience (ADE) reporting deficiencies, including failure to submit serious and unexpected reports within the required fifteen-day timelines, underscoring expectations for timely safety reporting and robust documentation.
It is Lachman’s experience that the current, volume-driven reports being experienced by clients can be difficult to manage. The rapid escalation in volume and inevitable, clinical diversity of reports can potentially overwhelm traditional (people/paper-based) systems, which can result in significant compliance risk and potential citations from regulators.
The Risks of Decentralized PV Operations
Many companies entering the GLP-1 space rely on distributed operating models involving regional affiliates, licensing partners, Contract Manufacturing Organizations (CMOs), vendors, and external call centers. In practice, this setup is common. The challenge is maintaining consistency across all of these groups, which is a regulatory expectation.
Safety information can come from almost anywhere—medical information lines, product complaints, social media channels, partner organizations, or support programs. Each source may follow slightly different procedures, use different terminology, or collect different levels of detail.
Over time, inconsistencies may start to appear. Coding practices may vary between teams; reports may be incomplete or information may not move quickly enough between systems. Such gaps can affect the quality and reliability of the global safety database.
Signal detection becomes harder to perform if data is fragmented or not standardized properly, and emerging trends of side effects may not be visible early enough. Important signals can get lost, buried in the volume of complaints, or split across disconnected systems.
Without strong governance and a clearly defined operating structure, decentralized PV programs can easily become overwhelmed and pushed out of date.
Common Failure Points During Rapid Market Expansion
One recurring issue in fast-growing blockbuster programs, such as GLP-1s, is that companies often underestimate how much infrastructure pharmacovigilance requires. PV teams are often understaffed relative to incoming volume, especially early after launch. Backlogs begin to develop, timelines tighten, and teams end up operating in a constant reactive state.
Another common problem is delayed partner integration. Affiliates or vendors may be added to the process after systems are already established, creating inconsistencies in responsibilities, reporting expectations, and data-handling procedures.
Complaint handling is a related quality system where gaps frequently appear. If product complaints and adverse events are not investigated and reconciled properly, reportable safety information can be missed or underreported. Regulators tend to focus heavily on this during inspections.
Importantly, inspectors are not only reviewing reported metrics. They are evaluating whether the overall PV system demonstrates control, consistency, and sustainable oversight under real operating conditions.
How Lachman Supports Organizations in This Environment
In this blockbuster market, pharmacovigilance is no longer functioning quietly in the background. Companies that invest early in scalable systems and stronger governance structures are generally in a better position to manage regulatory expectations as reporting volumes continue to grow.
Lachman can help build scalable PV operating models, modernize data and technology platforms, and strengthen governance and compliance frameworks to ensure that global regulatory compliance is met. Contact us today at LCS@LachmanConsultants.com to connect with our specialized team.
